REGN
Regeneron Pharmaceuticals
$612.50
▲ 0.4%Updated Today 7:15 PM ET
▲ Up 18.8% over the last 12 months
Market Cap
$63.95B
P/E
14.43x
Forward P/E (est.)
13.82x
ROE
14.3%
Revenue Growth
5.9%
EPS Growth
4.4%
Profit Margin
29.6%
FCF Yield
6.3%
Debt / Equity
0.09x
ROIC
8.0%
Interest Coverage
49.01x
Current Ratio
3.57x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
2.5%
Rating Score
69/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what REGN's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. REGN trades near $612.50, below its 50-day average ($683.35) and 200-day average ($696.91). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 44 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. REGN's is $16.10 (~2.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month REGN found buyers near $591.52 (support) and sellers near $651.00 (resistance); its 52-week range is $503.25–$821.11. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.1× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Regeneron Pharmaceuticals (REGN) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $63.95B.
In its latest reported year it generated about $14.34B in revenue and $4.50B in net profit.
Our model rates REGN Favorable (69/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-2.8%
Revenue moved from $16.07B in 2021 to $14.34B in 2025, a -2.8% compound annual growth rate. The most recent year grew a steady 5.9% year over year. Slower, mature growth is common for established businesses.
Gross Margin
85.7%
Operating Margin
24.9%
Net Margin
31.4%
ROE
14.3%
Regeneron Pharmaceuticals keeps about 29.6% of each sales dollar as net profit, with a 85.7% gross margin and 24.9% operating margin. Return on equity is 14.3% and return on invested capital about 8.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$1.99B
Net Debt
-$976.40M
Net cash position
Net Debt / EBITDA
-0.27x
Debt / Equity
0.09x
Leverage: debt-to-equity is 0.1x, and operating profit covers interest about 49.0x, with a current ratio of 3.6x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $1.99B of total debt against $2.96B of cash.
Operating CF
$4.98B
Free Cash Flow
$4.08B
FCF Margin
28.4%
In the latest year Regeneron Pharmaceuticals produced about $4.98B of operating cash flow and $4.08B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
14.43x
P/S
4.48x
P/B
2.58x
EV / EBITDA
15.4x
REGN trades at 14.4x trailing earnings (about 13.8x on estimated forward earnings), 4.5x sales, and 2.6x book value. Reverse-engineering today's price implies the market expects roughly 2.5% long-term free-cash-flow growth. That is an undemanding multiple — potentially cheap if the business is stable.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How REGN stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), REGN ranks #7 of 59 by our overall rating. It trades at a discount versus the sector on earnings (14.4x P/E vs. 25.4x median) with a lower return on equity (14.3% vs. 14.9%) and slower revenue growth (5.9% vs. 7.9%).
P/E vs sector
14.4x
median 25.4x
ROE vs sector
14.3%
median 14.9%
Growth vs sector
5.9%
median 7.9%
Sector rank
#7
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$506.64 – $886.62
vs. $612.50 today · expected CAGR -4% – 8%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $15.20B | $16.12B | $17.08B | $18.11B | $19.19B |
| Net income | $4.71B | $5.00B | $5.30B | $5.61B | $5.95B |
| EPS | $50.16 | $53.17 | $56.36 | $59.75 | $63.33 |
| Share price (low) | $401.30 | $425.38 | $450.91 | $477.96 | $506.64 |
| Share price (high) | $702.28 | $744.42 | $789.09 | $836.43 | $886.62 |
| CAGR (low–high) | -34% / 15% | -17% / 10% | -10% / 9% | -6% / 8% | -4% / 8% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for REGN:
- High net margins (29.6%) point to pricing power or efficiency.
- Healthy free-cash-flow yield (~6.3%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- Our model's overall read is Favorable (69/100).
The case against REGN:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Regeneron Pharmaceuticals is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 14.4x earnings, which our model scores Favorable (69/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.